Education
About Us
Working with TipRanks
Follow Us
Alterity Therapeutics Ltd (ATHE)
NASDAQ:ATHE
ATHE Stock Chart & Stats
$3.55
-$0.16(-4.23%)
At close: 4:00 PM EST
$3.55
-$0.16(-4.23%)
Day’s Range― - ―
52-Week Range$2.52 - $7.00
Previous CloseN/A
Volume131.33K
Average Volume (3M)13.05K
Market Cap
$61.63M
Enterprise Value$27.09M
Total Cash (Recent Filing)$49.15M
Total Debt (Recent Filing)$98.35K
Price to Earnings (P/E)―
Beta1.17
Next Earnings
Mar 04, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.07
Shares Outstanding18,125,694
10 Day Avg. Volume16,981
30 Day Avg. Volume13,055
Financial Highlights & Ratios
PEG Ratio0.09
Price to Book (P/B)1.56
Price to Sales (P/S)12.18
P/FCF Ratio-5.79
Enterprise Value/Market Cap0.44
Enterprise Value/Revenue7.07
Enterprise Value/Gross Profit7.30
Enterprise Value/Ebitda-1.36
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.18
Revenue Forecast (FY)$2.64M
Bulls Say, Bears Say
Bulls Say
Innovative Drug DevelopmentAlterity's unique approach to treating neurodegenerative diseases positions it as a leader in innovation, potentially leading to breakthrough therapies and a competitive edge in the biotechnology sector.
Positive Clinical Trial ResultsSuccessful Phase 2 results for ATH434 enhance Alterity's credibility and market potential in treating Multiple System Atrophy, supporting long-term growth and market leadership.
Strong Revenue GrowthHigh gross profit margins indicate effective cost management and strong revenue growth, which are critical for sustaining operations and funding future R&D activities.
Bears Say
Profitability ChallengesPersistent unprofitability raises concerns about Alterity's ability to sustain operations and invest in future growth, posing a risk to long-term viability.
Negative Cash FlowsNegative cash flows indicate liquidity issues, potentially limiting Alterity's ability to fund ongoing research and development, impacting its growth trajectory.
High Operational RiskOngoing operational losses and cash flow issues increase financial risk, potentially affecting Alterity's ability to achieve long-term strategic goals and maintain competitive positioning.
Alterity Therapeutics News
ATHE FAQ
What was Alterity Therapeutics Ltd’s price range in the past 12 months?
Alterity Therapeutics Ltd lowest stock price was $2.52 and its highest was $7.00 in the past 12 months.
What is Alterity Therapeutics Ltd’s market cap?
Alterity Therapeutics Ltd’s market cap is $61.63M.
When is Alterity Therapeutics Ltd’s upcoming earnings report date?
Alterity Therapeutics Ltd’s upcoming earnings report date is Mar 04, 2027 which is in 348 days.
How were Alterity Therapeutics Ltd’s earnings last quarter?
Alterity Therapeutics Ltd released its earnings results on Feb 25, 2026. The company reported -$0.067 earnings per share for the quarter, the consensus estimate of -$0.067 by $0.
Is Alterity Therapeutics Ltd overvalued?
According to Wall Street analysts Alterity Therapeutics Ltd’s price is currently Overvalued.
Does Alterity Therapeutics Ltd pay dividends?
Alterity Therapeutics Ltd does not currently pay dividends.
What is Alterity Therapeutics Ltd’s EPS estimate?
Alterity Therapeutics Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Alterity Therapeutics Ltd have?
Alterity Therapeutics Ltd has 18,125,694 shares outstanding.
What happened to Alterity Therapeutics Ltd’s price movement after its last earnings report?
Alterity Therapeutics Ltd reported an EPS of -$0.067 in its last earnings report, expectations of -$0.067. Following the earnings report the stock price went up 2.945%.
Which hedge fund is a major shareholder of Alterity Therapeutics Ltd?
Currently, no hedge funds are holding shares in ATHE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Alterity Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
43.18%
12-Months-Change
Fundamentals
Return on Equity
-30.19%
Trailing 12-Months
Asset Growth
481.25%
Trailing 12-Months
Company Description
Alterity Therapeutics Ltd
Alterity Therapeutics (ATHE) is a biotechnology company focused on developing innovative therapies for neurodegenerative diseases, particularly in the realm of protein misfolding disorders. The company operates primarily in the healthcare sector, leveraging its proprietary drug development platform to create novel treatments aimed at addressing unmet medical needs in conditions such as Alzheimer's disease and Parkinson's disease. Alterity's core pipeline includes drug candidates that target specific molecular mechanisms involved in these disorders, with the goal of improving patient outcomes and quality of life.
Technical Analysis
Ownership Overview
―
Insiders
<0.01% Mutual Funds
1.27% Other Institutional Investors
98.73% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---